Last reviewed · How we verify
GLPG0187
At a glance
| Generic name | GLPG0187 |
|---|---|
| Sponsor | Galapagos NV |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- GLPG0187: Safety, Tolerability and Pharmacokinetics in Patients With Solid Tumors (PHASE1)
- Bioavailability Study of Prodrug of GLPG0187 in Healthy Volunteers (PHASE1)
- First-in-Human Single Ascending Subcutaneous (s.c.) Dose and Single Oral Dose of GLPG0187 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GLPG0187 CI brief — competitive landscape report
- GLPG0187 updates RSS · CI watch RSS
- Galapagos NV portfolio CI